Fidelity
Home > Boards > Free Zone > Health and Sciences > Biotech Values

Normally I'd agree - but on 3yr paper

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
10nisman Member Profile
 
Followed By 6
Posts 1,491
Boards Moderated 0
Alias Born 10/26/03
160x600 placeholder
Johnson & Johnson Earnings Rise 35%
Johnson & Johnson earns $4.73 billion, or $1.64 a share, led by continued sales growth in its pharmaceutical business. Revenue increased 3.5% to $18.12 billion. It also lifted its EPS estimate range for the year.
More Top Equities Stories Of The Day
GM's Barra Unveils Further Plans to Improve Safety
Glencore Xstrata Buys Caracal -- Update
Citi Picks Dewilde to Lead Asia Markets and Investor Services Business
Sales of Johnson s New Hepatitis Drug Soars
Twitter Co-Founders, CEO Won't Sell Shares -- 2nd Update
Columnist Joanna Stern answers readers' technology questions
Surgical Device Maker ConMed Exploring Sale -Reuters
Yahoo Shows Signs of Growth
10nisman   Thursday, 09/23/10 12:08:13 PM
Re: wallstarb post# 104887
Post # of 176849 
Quote:
Normally I'd agree - but on 3yr paper it doesnt have the duration for a longer term investment, and unless MSFT is buying junk bonds with it I really dont see the point for them. Perhaps an acquisition on the horizon - or maybe they are buying some CMOs

The vast majority of MSFT's cash is overseas and thus to get around paying taxes to repatriate it they chose to issue debt at insanely attractive levels. MSFT will likely use the cash to pay its dividend and buy-back shares.

10nis

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist